Financial Gravity Asset Management’s Myriad Genetics MYGN Stock Holding History

Financial Gravity Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-616	Closed	-$2.99K	–	976
2021 Q4	$2.99K	Buy	+616	New	+$17.8K	0.07%	284
2021 Q1	–	Sell	-1	Closed	–	–	851
2020 Q4	$0	Buy	+1	New	+$16	﹤0.01%	611
2020 Q2	–	Sell	-9	Closed	-$126	–	562
2020 Q1	$126	Sell	9 -27	-75%	-$570	﹤0.01%	852
2019 Q4	$27K	Sell	36 -360	-91%	-$9.9K	0.02%	907
2019 Q3	$11K	Sell	396 -509	-56%	-$14.8K	0.01%	598
2019 Q2	$25K	Sell	905 -786	-46%	-$22.2K	0.02%	448
2019 Q1	$56K	Buy	+1,691	New	+$51.5K	0.05%	287
2018 Q3	$6K	Sell	137 -1,064	-89%	-$47.3K	0.01%	693
2018 Q2	$51K	Buy	1,201 +1,029	+598%	+$34.8K	0.05%	317
2018 Q1	$5K	Buy	+172	New	+$5.82K	0.01%	737

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Financial Gravity Asset Management's MYGN Position: Q1 2022 in Review

Financial Gravity Asset Management sold out of Myriad Genetics (MYGN) in Q1 2022, closing a stake of 616 shares — an estimated $2.99K sold.

Financial Gravity Asset Management first reported a position in MYGN in Q1 2018 and held it in 10 quarters. The position peaked at $56K in Q1 2019. 205 funds tracked by Wall St. Rank hold MYGN as of Q1 2022.

Financial Gravity Asset Management reported no remaining Myriad Genetics position as of Q1 2022 after selling out during the quarter.
Financial Gravity Asset Management sold 616 Myriad Genetics shares in Q1 2022, an estimated $2.99K.
Financial Gravity Asset Management first reported a position in Myriad Genetics in Q1 2018 and held it in 10 quarters.
Financial Gravity Asset Management's Myriad Genetics position peaked at $56K in Q1 2019.
205 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2022.

Based on Financial Gravity Asset Management's 13F filing for Q1 2022, filed 13 May 2022.